Behind-The-Counter Sale Works Without Regulation – Former FDA Counsel
This article was originally published in The Tan Sheet
Executive Summary
FDA's interest in establishing an official third class of drugs, as well as the OTC industry's concern about the idea, could be diminished because the agency already allows a path to behind-the-counter sales in new drug and switch applications, according to a former FDA chief counsel